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ABSTRACT

The genome is constantly damaged by intracellular and extracellular factors. At
sites of DNA damage, replication forks are stalled, leading to monoubiquitination of
proliferating cell nuclear antigen (PCNA). Monoubiquitination of PCNA promotes the
switch from regular high-fidelity polymerases to Y-family polymerases for bypassing
damaged DNA. Prolonged replication by these polymerases may lead to increased
mutagenesis, so tight regulation of this process is required. ATAD5 recruits a
deubiquitinase complex consisting of ubiquitin-specific protease 1 (USP1) and USP1associated factor 1 (UAF1) to control PCNA monoubiquitination. The mechanism by
which ATAD5 and PCNA interact has been previously unexplored. We show through
biochemical and structural studies that ATAD5 contains a non-canonical PCNAinteracting protein motif that interacts with PCNA in the low µM range. Our structural
studies indicate that the binding of ATAD5’s PIP Box to PCNA is topologically conserved
with respect to canonical PIP Boxes from other proteins. Furthermore, we detected we
interactions between ATAD5’s and UAF1’s protein interacting motifs. This suggests that
ATAD5 acts as an adapter between PCNA and the UAF1-USP1 deubiquitinase complex.
Characterization of these interactions will increase our understanding of DNA damage
tolerance and may lead to the design of better cancer therapeutics.
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CHAPTER 1: INTRODUCTION
1.1 Translesion DNA Synthesis
Faithful replication of a cell’s genetic material during replication is essential in
order to pass genetic material from one generation to the next; however, DNA-damaging
agents constantly injure the genome. High fidelity replication of the cell’s genetic material
is normally carried out through the combination of accurate DNA polymerases and DNA
mismatch repair (1). These high-fidelity DNA polymerases have evolved mechanisms to
strongly favor correct dNTP incorporation opposite to the template strand during
replication (1). However, these polymerases are unable to replicate past damaged DNA,
and are stalled at these sites (2). Stalled replication forks are dangerous as they can collapse,
causing chromosomal breaks and genomic instability (3).
Cells belonging to all branches of life possess DNA damage tolerance (DDT)
pathways in order to survive in the presence of DNA-polymerase blocking lesions and to
restart stalled replication forks (4). One of the DDT pathways is the translesion synthesis
(TLS) pathway, which involves the use of specialized DNA polymerases, most of which
belong to the Y-family (5). Y-family polymerases differ from other polymerases in that
they are able to replicate past DNA lesions and have reduced fidelity on undamaged
templates (6). Prolonged replication by these low-fidelity polymerases could have
deleterious consequences arising from mutations, so it is crucial that their activity is strictly
regulated (6). The specific mechanism in which different polymerases are loaded on and
off of the replication fork involves post-translational modification of proliferating cell
nuclear antigen (PCNA) (7).
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1.2 Proliferating Cell Nuclear Antigen
PCNA is a DNA sliding clamp with multiple functions in DNA replication and
repair. Two separate groups first identified PCNA independently from each other. The first
group, Miyachi et al. (1978), observed an auto-antigen in the nucleus of dividing cells from
patients with systemic lupus erythematosus and named it PCNA (8). The second group,
Bravo and Celis (1980), identified a protein that was synthesized during the S-phase of the
cell cycle using two-dimensional gel electrophoresis and named it cyclin (9). Work by
Mathews et al. (1984) later demonstrated that the two proteins discovered by these groups
were the same (10). Today the protein is called PCNA, as the term cyclin is now reserved
for a family of proteins involved in cell cycle regulation (11).
PCNA has functions at various levels of DNA metabolic pathways while unbound
or bound to DNA. When unbound to DNA, PCNA promotes the localization of replication
factors with PCNA-binding domains to replication factories (12). When bound to DNA,
PCNA directs proteins involved in DNA replication, repair, modification, and chromatin
modeling (12). PCNA is the processivity factor of Polδ and is therefore the functional
homologue of other processivity factors such as the β subunit of E. coli DNA polymerase
III holoenzyme (Pol III) and the gene-45 product of bacteriophage-T4 (11). Stukenberg et
al. (1991) first established the concept that a processivity factor functions by encirculating
DNA through experiments on the β subunit of E. coli Pol III (13). They demonstrated that
the β subunit bound tightly to nicked circular plasmid, however, the clamp dissociates off
of DNA by sliding over the ends upon linearization of the plasmid (13). The determination
of the crystal structure of the β subunit confirmed these studies and revealed that it is a
homodimeric ring (14).
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1.2.1 Human PCNA Structure
The ortholog of the β subunit of Pol III in eukaryotes is PCNA. Although the
sequence similarity between these two proteins is limited, they are structurally similar.
Human PCNA consists of three identical monomers instead of two (Figure 1A) (15). Each
monomer of human PCNA contains two similar domains, giving the complete protein a
six-fold pseudo symmetry (Figure 1C) (12). Each of the domains is composed of a series
of antiparallel β strands forming curved β sheets. Six curved β sheets make up a donut-like
scaffold. Two alpha helices from each domain face inward approximately perpendicular to
the face of the ring to form a cylindrical inner cavity with a diameter of about 34 Å. This
is much larger than the diameter of double stranded B DNA (20 Å). Although PCNA has
a net negative charge, the inner cavity is electrostatically positive. Up to 10 positively
charged amino acid side chains face toward the center from the alpha helices, however,
there are only three negatively charged amino acids to counteract the charge. The positively
charged ring forms favourable interactions through the solvent to the negatively charged
phosphodiester backbone of DNA (12).
PCNA has a distinct back and front face (Figure 1B). The front face of PCNA is
oriented in the direction of DNA synthesis and contains structural elements that are
involved in many protein interactions (16). The C-terminal tails of the monomers face
frontward along with an interdomain connecting loop (IDCL) which links the N- and Cterminals of each monomer (12). The IDCL covers a hydrophobic pocket, which can be
“plugged” by proteins containing a PCNA-interaction protein motif (PIP box) (15).
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Figure 1. Structure of native human PCNA (PDB ID: 1W60). Each monomer is coloured
differently. A) Cartoon representation with transparent surface of the front (top) and back
(bottom) view of PCNA showing the diameter of the inner ring. B) Side view of PCNA
with the front and back labelled. C) Front view of PCNA monomer. The two similar
globular domains have been divided by a dotted line. N- and C- terminals are indicated in
bold.
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1.2.2 PCNA-interacting protein motif (PIP box)
Virtually all proteins that interact with PCNA contain a PCNA-interacting protein
motif termed the “PIP box”. The consensus binding motif of the PIP box is:
Qxx[Ψ]xx[ϑ][ϑ] (x being any amino acid, ψ being the hydrophobic residues L, M, or I and
ϑ being the aromatic residues F or Y (17). In some cases, instead of being C-terminally
flanked by xx[ϑ][ϑ], the Qxx[Ψ] motif can be flanked by KAx instead (18). A sequence
alignment of human proteins that interact with PCNA is shown in Figure 2. Gulbis et al.
(1996) first published a crystal structure that revealed how the PIP box interacts with
PCNA using a peptide derived from p21WAF1/CIP1 (p21), an inhibitor of the cyclindependent kinases that control the initiation of S phase and DNA replication (19). This
peptide binds PCNA with high affinity, the interaction has a Kd in the low nanomolar range
(15, 20). The PIP box of this peptide was shown to form an alpha helix that acts as a
hydrophobic plug, docking into the hydrophobic pocket on PCNA. Furthermore, the Cterminal of this peptide forms a β sheet structure that makes extensive contacts with the
IDCL (15). Proteins that interact with PCNA through a PIP box may also use additional
regions for interaction (21). Because many proteins that contain PIP boxes bind to PCNA
in the same region, the binding is often mutually exclusive and competitive (21).
Many of the pathways which PCNA is part of involves the transfer of DNA from
one enzyme to another. For example, during Okazaki fragment processing, FEN1 must
cleave the 5’ flap on DNA before DNA ligase can patch the nick (22). One possibility of
how this occurs is that PCNA acts as a “toolbelt”, binding all the necessary enzymes
required to facilitate the transfer of the substrate (22). This has been observed in
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Consensus

QxxΨxxϑϑ

p21
Poi∂
FEN1
WRN
RecQ
MSH6
MSH3
Ligl
UNG2

RKRRQTSMTDFYHSKR
KANRQVSITGFFQRKQGSTQGRLDDFFKVTG
IEGDQWKLLRDFLLRD
KEEAQNLIRHFFHGRA
-MSRQSTLYSFFPKSP
APARQAVLSRFFQSTG
---MQRSIMSFFHPKK
-MIGQKTLYSFFSPSP

RFC
Polι
Polη
Polκ
ATAD5

-----MDIRKFFGVIP
--CAKGLIDYYLMPSL
RPEGMQTLESFFKPLT
PNPPKHTLDIFFK--APPKPSNILDYFRKTS

Figure 2. Sequence alignment of human proteins containing PIP boxes. The consensus
sequence is shown with the alignment, where x being any amino acid, ψ being the
hydrophobic residues L, M, or I and ϑ being the aromatic residues F or Y. Canonical PIP
box residues are coloured blue at positions 1, 4, 7 and 8. Canonical and non-canonical PIP
boxes are separated.
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S. solfataricus where a PCNA heterotrimer simultaneously binds to DNA polymerase,
FEN1, and DNA ligase (23). However, There is currently no clear evidence that suggests
eukaryotic PCNA functions as a toolbelt, however, it is likely (22).

1.2.3 Post-translational modification of PCNA
PCNA is post-translationally modified in response to stalling of the replication fork
via sumoylation or monoubiquitination (24). As previously mentioned, prolonged stalling
of the replication fork during DNA replication is dangerous as it can collapse. This causes
double-stranded breaks and gross chromosomal rearrangements which may lead to cell
death (3). Restart of the replication fork is possible through post-translational modification
of PCNA and subsequent activation of one of two DDT pathways. These pathways include
the homologous recombination repair pathway through sumoylation of K164 or the postreplication repair pathway via monoubiquitination of the same lysine residue (25, 26). As
seen in Figure 3A, monoubiquitination of K164 is carried out by E2 ubiquitin conjugating
enzyme Rad6 and E3 ubiquitin ligase Rad18 (Rad6/Rad18 complex) in the RAD6 pathway
(25). Rad18 recruits the ubiquitination machinery to DNA-bound PCNA through
interactions with Rad6, PCNA, and DNA (27). The structure of mono-ubiquitinated PCNA
is shown in Figure 3B.
Monoubiquitinated PCNA (ubPCNA) has been proven to promote TLS carried out
by Y-family polymerases. In addition to the PIP box motif, these polymerases also contain
ubiquitin-binding motifs (UBMs) or ubiquitin-binding zinc fingers (UBZ) which are able
to interact with the ubiquitin moiety and increase its affinity to ubPCNA (24). Tight
regulation of TLS polymerases is required, as prolonged replication by these error-prone
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A
Rad6/
Rad18
UAF1-USP1

B

Ubiquitin

Ubiquitin

Figure 3. PCNA ubiquitination is regulated by the RAD6 pathway and the UAF1-USP1.
A) PCNA is monoubiquitinated through the Rad6 pathway and deubiquitinated through the
recruitment of the UAF1-USP1 deubiquitinase (DUB) complex. B) Structure of
monoubiquitinated PCNA (PDB ID: 3TBL). Ubiquitin molecules (orange) are covalently
linked to K164 of PCNA (blue) on two of three monomers.
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polymerases may lead to increased mutagenesis. Zhuang et al. (2008) demonstrated that
the switching from the TLS polymerase η (Polη) to the normal high-fidelity Polδ is
inhibited by the ubiquitin moiety on PCNA (28). This suggests that deubiquitination is
required for the normal high-fidelity polymerase to switch back to DNA synthesis after
lesion bypass. Ubiquitin specific protease 1 (USP1) was identified in a siRNA screen as a
putative deubiquitinase (DUB) for PCNA (29).

1.3 Ubiquitin-Specific Protease 1 (USP1) and USP1 Associated Factor (UAF1)
Complex
DUB enzymes control deubiquitination of human proteins. Although 95 distinct
proteins belong to this family of proteins, many of their functions are unknown (30). DUBs
are cysteine proteases that remove ubiquitin from their substrate, either from mono- or
poly- ubiquitinated proteins or from linear ubiquitin polypeptides (29).
USP1 is a DUB that negatively regulates PCNA monoubiquitination in vivo and in
vitro (29). Upon DNA damage, transcription of USP1 is immediately turned off leading to
a rapid decay of USP1. This allows for PCNA to become monoubiquitinated, which is
essential for translesion synthesis (31). Knockdown of USP1 increases mutation frequency
during DNA replication and causes increased levels of ubPCNA (29). USP1 is activated
through interaction with USP1 associated factor 1 (UAF1). UAF1 stabilizes USP1 and is
essential for its deubiquitinating activity. UAF1 is also part of the Fanconi Anemia pathway
in charge of FANCD2 deubiquitination (30). USP1 alone has very low enzymatic activity,
however when it is part of a complex with UAF1, its activity increases 35-fold. This
increase is due to an 18-fold increase in catalytic turnover, and 2-fold increase in the
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proteins affinity to its substrate (31). The UAF1-USP1 DUB complex is likely recruited to
ubiquitinated PCNA through its interaction with ATAD5 (32).
UAF1 has an N-terminal WD40 domain containing eight WD40 propeller
sequences and two consecutive SUMO-like domains (SLD1 and SLD2) in its C-terminal
(Figure 4). The N-terminal binds and stimulates USP1’s ubiquitin protease activity (33).
Of the two SLDs in the C-terminal of UAF1, only the second SLD interacts with a SUMOinteracting motif (SIM) on ATAD5.

1.4 ATPase family, AAA domain-containing protein 5 (ATAD5)
ATPase family, AAA domain-containing protein 5 (ATAD5) is the human
homolog of the yeast protein enhanced levels of genomic stability 1 (Elg1). Elg1 is divided
into three main domains: an extended N-terminal domain, a central AAA+ ATPase domain,
and a C-terminal domain (Figure 4) (34). Elg1 was originally identified in a screen for
suppressors of chromosomal instability and is a protein which participates in telomere
maintenance in yeast (35, 36). Elg1 has also been suggested to form an RFC-like complex,
which functions in stabilization of the DNA replication fork. This RFC-like complex
unloads PCNA from DNA following Okazaki fragment ligation in DNA lagging strand
synthesis (37, 38). Knockdown of ATAD5 in mammalian cells leads to spontaneous
chromosomal breaks, increased levels of recombination and aberrations in the chromosome
such chromosomal fusions and inversions (39, 40).
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A

B

Figure 4. Schematic of ATAD5 and UAF1. A) Schematic diagram of ATAD5 with PCNAinteracting Protein (PIP) Box and sumo-interacting protein motif (SIM) coloured green and
yellow respectively. B) Schematic diagram of UAF1 with WD domains coloured orange
and sumo-like domains coloured blue.
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Knockdown of ATAD5 also causes PCNA and ubPCNA accumulate on DNA (41).
Consequently, the lifespan of replication factories (that use PCNA as a scaffold) is
extended, and remains well into G2 phase of cell division (41). The increase in PCNA
suggests that ATAD5 may interact with the core subunits of the RFC (rfc2-5) to form an
RFC-like complex, which is responsible for unloading PCNA similar to its yeast
homologue (41). Any binding of ATAD5 to PCNA has yet to be investigated, however, a
non-canonical PIP box motif has been shown to interact with PCNA in yeast (26, 34). The
accumulation of ubPCNA on DNA is due to ATAD5’s role in recruiting the UAF1-USP1
DUB complex.
ATAD5 interacts with UAF1 through a interaction similar to how the small
ubiquitin-like molecule (SUMO) interacts with a SIM: a SIM located in the N-terminal of
ATAD5 interacts with a SUMO-like domain (SLD) of UAF1 (32). The SIM consists of a
hydrophobic core, consisting of 3-4 aliphatic residues, juxtaposed to a negatively charged
cluster of acidic residues (42). The binding site of ATAD5 (KSNVVIQEEELELAVLE)
conforms to the consensus sequence of a SIM, and it is highly conserved among species
(43).
We have previously identified a putative PIP box motif in our lab in the N-terminal
of ATAD5 (Figure 2). Work done by Haley McConkey showed that a short peptide
containing this putative motif fused to GST was able to interact with PCNA in an affinity
pull-down assay. Furthermore, she showed that mutations to the two hydrophobic residues
at position 7 and 8 of this motif abolished the binding.
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1.5 Scope of thesis
Although it is proposed that ATAD5 functions to unload PCNA and recruit the
UAF1-USP1 DUB complex to ubPCNA, little is known about the interaction between
ATAD5 and PCNA. In yeast, Elg1 binds to PCNA through a non-canonical PIP box similar
to that of rfc1, a subunit of the RFC complex. PCNA has many binding partners, and
regulation of which protein binds at a given time is essential for certain cellular processes
such as the post replication repair or DDT pathways and DNA replication to occur.
Elucidation of the structural basis in which ATAD5 binds to PCNA and UAF1 can then be
applied to other proteins that bind to it.
The goal of this study is to elucidate the physical and functional relationships
between the binding of the human proteins: ATAD5, PCNA and UAF1, through structural
and biochemical methods. The ultimate objective of this study is to contribute
to our understanding of how the cell is able to recruit Y-family polymerases to stalled
replication forks arising from DNA lesions and facilitate switching from high- to low- and
back to high-fidelity polymerases.

1.6 Hypothesis
As seen in the sequence alignment of ATAD5’s PIP box with other human PCNAbinding proteins, ATAD5 contains a putative PIP box motif close to its N-terminal that
resembles those of the Y-family polymerases and rfc1 (Figure 2). Furthermore, ATAD5
contains a SIM-like motif that interacts with a SLD on UAF1. Therefore, we propose that
ATAD5 serves as an adaptor protein (Figure 5) that is able to bind both PCNA and UAF1.
We aim to characterize the physical interaction between the PIP box and SIM motif on the
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N-terminal of ATAD5 with PCNA and UAF1 through various biochemical methods.
Finally, we aim to elucidate the structural features of the binding between these proteins
through macromolecular crystallographic techniques.
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Figure 5. Schematic diagram of ATAD5 acting as an adaptor protein between
monoubiquitinated human PCNA and the UAF1-USP1 DUB complex. ATAD5 contains a
sumo-interacting motif (SIM) that interacts with the second sumo-like domain (SLD2) on
UAF1 as well as a PCNA-interacting protein motif (PIP box) that interacts with PCNA.
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CHAPTER 2: MATERIALS AND METHODS
2.1.1 Bacterial strains and plasmids
The plasmid expressing full-length wild-type PCNA was previously subcloned
from pAVR38, a generous gift from Dr. Roger Woodgate of the National Institutes of
Health (Maryland, USA), into pET22b. The pMCSG9, pMCSG10, pBluescriptR_UAF1
and pANT7-cGST-ATAD5 plasmids were purchased from the PlasmID Repository
(Harvard Medical School, Massachusetts, USA). Bacterial strain BL21(DE3) was
commercially purchased from Novagen. The maps of the vectors used are available in the
appendix (Figure I-II). A schematic diagram of the various domains from ATAD5 and
UAF1 used in this study are depicted in Figure 4.

2.1.2 Yeast strains and plasmids
The PJ694A yeast strain, and pASI and pACT2 vectors were generously provided
by Dr. Chris Brandl of the Schulich School of Medicine and Dentistry (Western University,
Ontario, Canada).

2.1.3 List of buffers
Buffers used in the purification of proteins and experiments have been compiled in
Table 1.

Table 1. Summary of buffers used in this study.*
Buffer

Used In

Components

Buffer A
Buffer B
Buffer C
Buffer D
Buffer E
Buffer F
Buffer G
ITC Buffer
HIS Buffer A

25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40
25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl
50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40
50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl
25 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT
300 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT
25 mM Tris pH 7.5, 150 mM NaCl, 10 % Glycerol, 1 mM EDTA, 1 mM DTT
25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM β-Me
25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me

Pull-Down Buffer
GST Elution Buffer

PCNA purification
PCNA purification
PCNA purification
PCNA purification
PCNA purification
PCNA purification
PCNA purification
ITC
MBP/GST-tagged
Protein purification
MBP/GST-tagged
protein purification
MBP/GST-tagged
Protein purification
MBP/GST-tagged
Protein purification
Pull-down assays
GST Purification

MBP Elution Buffer

MBP Purification

HIS Buffer B
Q Buffer A
Q Buffer B

25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me, 300 mM imidazole
25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me
25 mM Tris pH 7.5, 1 M NaCl, 1 mM EDTA, 7 mM β-Me
25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 5 mM β-Me
25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM reduced
glutathione
25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM maltose

*The referred name is listed under the “Buffer” heading, with the corresponding experiment and components in the columns on the
right.
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2.1.4 Cloning of constructs used in yeast two-hybrid assay
Plasmids pASI-PCNA, pASI-UAF1_SLD2, pACT2-ATAD5_N250, pACT2ATAD5_N498 were made through traditional “cut and paste” cloning. Appropriate gene
segments were amplified with an addition of an appropriate restriction enzyme cut site by
PCR using the appropriate forward and reverse primers summarized in Table 2. The
cloning of these constructs followed a previously described protocol with minor
modifications (44).
In brief, the amplification was carried out with 1 ng of DNA template, 500 pM of
forward and reverse primer, 200 μM of dNTPs, and 1 U of i-MAXTM II DNA polymerase
(iNtRON) in 20 μL reactions. An initial touchdown protocol was applied to avoid nonspecific binding of the primer, followed by cycling conditions outlined by the
manufacturer. The annealing temperature for the PCR products varied depending on the
primers used (Table 2). The PCR products were then diluted and digested with BamHI and
XhoI along with the vectors (pASI and pACT2) for 2 hours at 37 oC. The digested DNA
was then purified from a 1.5 % agarose gel using the QIAquick® Gel Extraction Kit
(Qiagen Inc.). The DNA was then ligated into the appropriate vectors with T4 DNA ligase
(New England Biolabs Inc.) in a 3:1 molar ratio of insert to vector DNA. 5 μL of the
ligation reaction was transformed into competent DH5α cells and grown overnight at 37
C on LB agar plates supplemented with 100 μg/mL of ampicillin. The plasmids were then

o

harvested from 3 mL cultures grown from single colonies and confirmed by DNA
sequencing.

Table 2. Summary of constructs used for yeast two-hybrid experiments..*

Construct

Protein
(Mutation)

Amino Acid
Residues

pASI-PCNA

PCNA

pASI-UAF1_SLD2

UAF1

559-677

56

pASI-UAF1_SLD2M

UAF1 (K595E)

559-677

63

pACT2-ATAD5_N250

ATAD5

2-250

55

pACT2-ATAD5_N250M

ATAD5 (I62A,
Y65A, and F66A)

2-250

67

pACT2-ATAD5_N498

ATAD5 (2-498)

2-498

55

pACT2-ATAD5_SIM

ATAD5

340-406

56

TAnnealing (oC)
64

Primers (Forward and Reverse)
5’- taatggatccatatgttcgaggcgcgcctg -3’
5’- gctagttattgctcagcgg -3’
5’- ctgtacttccaatccatgcccaaattcaacaaaattcc -3’
5’- ttatccacttccaatttacgtggacttctgacggtaatg -3’
5’- ctccaagtccgagaagttatggaacatgtttatg -3’
5’- gttccataacttctcggacttggagcatgt -3’
5’- taatggatccatgtgggggtcctggccatg -3’
5’- ctgcatctcgagttaatctctagagtttgcatggc -3’
5’- gcactggatgcagcaagaaagacttcacccacaaatgagaag -3’
5’- tgctgcatccagtgcattactaggttttggtggagcaaaaacc -3’
5’- taatggatccatgtgggggtcctggccatg -3’
5’- ctgcatctcgagttatccctctctgtttttgcc -3’
5’- taatggatcctaccccgaattttcttgaaacaaaagc -3’
5’- ctgcatctcgagttatgctttcataaattgctgtctttc -3’

*Original protein as well as length of expressed protein are described. Annealing temperatures and primers used are listed. Mutations
are described in brackets and primers used for mutagenesis.
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After confirming that the products are correct, mutations to pASI-UAF1_SLD2 and
pACT2-ATAD5_N250 were introduced to make pASI-UAF1_SLD2M and pACT2ATAD5_N250M. The mutagenesis of these two primers was completed using overlap
extension PCR as previously described with minor modifications (45). The primers were
designed according to the mutagenic primer-incomplete polymerase extension (M-PIPE)
protocol (shown in Table 2 with the mutations underlined) (46).
Briefly, two reactions were set up for each mutation as previously described,
however one reaction contained the forward primer for the insert and the reverse primer
for mutagenesis, and the other reaction containing the opposite primer pairs. The two
reactions were then digested with DpnI for 2 hours at 37 oC to break down the methylated
template DNA. The two reactions were then purified from a 1.5 % agarose gel using the
QIAquick® Gel Extraction Kit (Qiagen Inc.) and combined to be used as the template for
the second PCR step. The same forward and reverse primers for insert amplification were
used in the second PCR. The products were then digested with BamHI and XhoI and ligated
into the appropriate vectors as previously described. Following transformation of the
plasmids into competent DH5α cells, plasmids were extracted from 3 mL overnight
cultures grown from single colonies. The plasmids were verified using DNA sequencing.

2.1.5 Cloning of constructs used for protein expression
The GST-fusion constructs pMCSG10-ATAD5_PIP, pMCSG10-ATAD5_PIPM
and pMCSG10-p21 were previously prepared by Guangxing Xing. The GST-fusion
construct pMCSG10-ATAD5_SIM and the MBP-fusion pMCSG9-UAF1_SLD2 were
prepared using primer incomplete polymerase extension (PIPE) cloning as previously
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described with modifications (46). All constructs used for protein expression are listed in
Table 3 along with the appropriate primers used (where available).
In brief, the insert for each construct was amplified using PCR with primers adding
sequences at the 5’ and 3’ ends complementary to the sequences added to the vectors. The
vector was also amplified as well. The amplifications were carried out with 1ng of template
DNA, 500 pM of forward and reverse primers, 200 μM of dNTPs, and 0.5 U of Q5 HighFidelity DNA Polymerase (New England Biolabs Inc.). The Q5 High GC Enhancer (New
England Biolabs Inc.) was added to the reactions to amplify the insert from pANT7-cGSTATAD5. Touchdown PCR was used to amplify the products with an annealing temperature
range from 65 oC to 55 oC. The products were then digested with DpnI for 2 hours at 37 oC
and only the vector was purified from a 0.7 % agarose gel using the QIAquick® Gel
Extraction Kit (Qiagen Inc.). The inserts were then mixed with the vectors and incubated
at room temperature for 5 minutes and on ice for 5 minutes. 5 uL of this mixture was then
transformed into competent DH5α cells and grown overnight at 37 oC. 3 mL cultures were
grown from single colonies and the plasmids were harvested and verified by DNA
sequencing.
The same mutation was made to UAF1’s SLD2 domain in pMCSG9-UAF1_SLD2
as in pASI-UAF1_SLD2 using overlap extension PCR as previously described to create
pMCSG9-UAF1_SLD2M.

Table 3. Summary of constructs used for protein expression and purification.

Protein
(Mutation)

Amino Acid
Residues

p21
ATAD5
ATAD5 (Y65A and
F66A)

51-75

pMCSG10-ATAD5_SIM

ATAD5

340-406

55

pMCSG9-UAF1_SLD2

UAF1

559-677

56

pMCSG9-UAF1_SLD2M

UAF1 (K595E)

559-677

63

Construct
pMCSG10-p21
pMCSG10-ATAD5_PIP
pMCSG10-ATAD5_PIPM

TAnnealing (oC)

Primers (Forward and Reverse)

51-75

5’- ctgtacttccaatcctctgatcctgagaatgaacag -3’
5’- ttatccacttccaatttaccaggtttcacagcttcag -3’
5’- ctgtacttccaatccatgcccaaattcaacaaaattcc -3’
5’- ttatccacttccaatttacgtggacttctgacggtaatg -3’
5’- ctccaagtccgagaagttatggaacatgtttatg -3’
5’- gttccataacttctcggacttggagcatgt -3’

*Original protein as well as length of expressed protein are described. Annealing temperatures and primers used are listed where
available. Mutations are described in brackets and primers used for mutagenesis.
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2.2 Expression and purification
2.2.1 Expression and purification of PCNA
BL21(DE3) E. coli cells containing the pRARE plasmid were transformed with
pET22b-hPCNA and incubated at 37 oC overnight. Colonies were picked and grown in a
50 mL starter culture of 2xYT media containing 100 μg/mL ampicillin and 25 μg/mL
chloramphenicol. The starter culture was used to inoculate 1 L of 2xYT media with the
same concentration of antibiotics, supplemented with 6 mM MgCl2. The cultures were
grown to an OD600 of 1.2 at 37 oC before induction with 0.5 mM isopropyl-1-thio-β-Dgalactopyranoside (IPTG) for 16 h at 30 oC. Cells were harvested by centrifugation at 4,500
g and the resulting cell paste was stored at -20 oC until further use.
Frozen cells were thawed on ice and resuspended in Buffer A (25 mM Tris pH 7.5,
1 mM EDTA, 7 mM β-Me, 0.01 % NP-40) containing 100 mM NaCl and 1 mM of the
protease inhibitor, phenylmethylsulfonyl fluoride (PMSF). The cell suspension was lysed
by three passages through a French press at 15,000 psi. The lysate was then clarified by
centrifugation at 20,000 rpm at 4 oC for 30 min. PCNA was then purified to near
homogeneity as previously described, with modifications (47).
In brief, the supernatant was loaded onto two 5 mL HiTrap Q HP columns (GE
Healthcare Life Sciences) pre-equilibrated with Buffer A containing 10 % Buffer B (25
mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me, 0.01 % NP-40, 1 M NaCl) for anion exchange
chromatography. The protein was eluted off of the columns using a gradient of Buffer B.
Fractions containing PCNA were pooled and diluted with Buffer C (50 mM NaAc pH 5.5,
10 % glycerol, 7 mM β-Me, 0.01 % NP-40) until the approximate NaCl concentration was
50 mM. This sample was applied to two 5 mL HiTrap Heparin HP columns and eluted with
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a gradient of Buffer D (50 mM NaAc pH 5.5, 10 % glycerol, 7 mM β-Me, 0.01 % NP-40,
1 M NaCl). The fractions containing the protein was pooled and dialyzed against Buffer E
(25 mM KH2PO4/K2HPO4 pH 7.0, 10 % glycerol, 1 mM DTT) overnight. The sample was
then loaded onto a packed 12 mL CHT ceramic hydroxyapatite Type I column. The protein
was eluted off of the column using a gradient of Buffer F (300 mM KH2PO4/K2HPO4 pH
7.0, 10 % glycerol, 1 mM DTT). Fractions containing the protein of interest were pooled
and concentrated and subjected to size exclusion chromatography on a SuperdexS200
10/300 GL equilibrated with Buffer G (25 mM Tris pH 7.5, 150 mM NaCl, 10 % Glycerol,
1 mM EDTA, 1 mM DTT).

2.2.2 Expression and purification of recombinant proteins
All plasmids constructed with the pMCSG9 and pMCSG10 vectors (Table 3) were
transformed into competent E. coli BL21(DE3) cells following standard protocols (48).
The same procedure was applied to all of the plasmids.
Single colonies were picked following transformation and grown as 5 mL cultures
overnight in LB media overnight supplemented with 100 μg/mL of ampicillin. These
cultures were then added to 1 L of the same media and grown to an OD600 of 0.8 at 37 oC
before being induced with 0.5 mM of IPTG for 16 hours at 16 oC. Cells were harvested by
centrifugation at 4,500 g and the resulting cell paste was stored at -20 oC until required for
further use.
The frozen cell paste was thawed on ice and the cells were resuspended in HIS
Buffer A (25 mM Tris pH 7.5, 500 mM NaCl, 1 mM EDTA, 7 mM β-Me) spiked with
1mM of the protease inhibitor, PMSF. The cell suspension was lysed by two passages
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through an Emulsiflex cell homogenizer (Avestin) at 15,000 psi. The lysate was then
clarified by centrifugation at 20,000 rpm at 4 oC for 30 min.

2.2.3 Purification of GST-p21, GST-ATAD5_PIP, GST-ATAD5_PIPM, and GSTATAD_SIM
Recombinant proteins were purified by immobilized metal affinity chromatography
(IMAC) followed by anion exchange chromatography following the manufacturer’s
suggested protocols. Briefly, clarified lysate was loaded onto two 5 mL prepacked
cOmplete His-tag purification columns (Roche) pre-equilibrated with HIS Buffer A and
washed with HIS Buffer A + 10 mM imidazole. Proteins were then eluted using HIS Buffer
B (25 mM Tris pH 7.5, 500 mM NaCl, 300 mM imidazole, 1 mM EDTA, 7 mM β-Me).
The eluents were diluted with Q Buffer A (25 mM Tris pH 7.5, 1 mM EDTA, 7 mM β-Me)
until the approximate NaCl concentration was 50mM and applied to two 5mL HiTrap Q
HP columns equilibrated with 5% Q Buffer B (25 mM Tris pH 7.5, 1 mM EDTA, 7 mM
β-Me, 1 M NaCl) and eluted with a gradient of Q Buffer B. The proteins were then
concentrated using centrifugation using Vivaspin 6 ultrafiltration devices with appropriate
molecular weight cut offs. The concentrated proteins were stored at -20 oC after spiking
the samples with glycerol to 50 %.

2.2.4 Purification of GST, UAF1_SLD2, UAF1_SLD2M, and ATAD5_SIM
The purification of GST, UAF1_SLD2, UAF1_SLD2M, and ATAD5_SIM
proteins followed the above protocol with slight modifications. After IMAC, His-tagged
TEV protease was added to GST-ATAD5_SIM, MBP-UAF1_SLD2, and MBP-
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UAF1_SLD2M at a 1:20 ratio and dialyzed against 5% Q Buffer B overnight to cleave the
GST and MBP tags. Each of the resulting samples were passed through two 5 mL
prepacked cOmplete His-tag purification columns (Roche) pre-equilibrated with HIS
Buffer A, removing the TEV protease and the His-tagged tags from the flow through. The
flow through fraction containing the cleaved protein was then diluted with Q Buffer A to a
NaCl concentration of approximately 50 mM and anion exchange chromatography was
performed as described above.
The remaining protein on the IMAC column was eluted with HIS Buffer B and
these fractions were applied to the appropriate prepacked columns (either MBPTrap HP
columns or GSTrap HP columns (GE Healthcare)) equilibrated with HIS Buffer A to
remove TEV Protease. Proteins were eluted with the appropriate buffers (GST Elution
Buffer (25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7 mM β-Me, 10 mM reduced
glutathione) or MBP Elution Buffer (25 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA, 7
mM β-Me, 10 mM maltose)). The buffer was exchanged and the proteins were concentrated
using centrifugation using Vivaspin 6 ultrafiltration devices with appropriate molecular
weight cut offs. The concentrated proteins were stored at -20 oC after glycerol was added
to a final concentration of 50 %.

2.3 Affinity pull-down
GST pull-down and His-affinity pull-downs were carried out using similar
protocols. 50 μg of GST-tagged protein (bait) was immobilized onto glutathione sepharose
resin equilibrated in Pull-Down Buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM
EDTA, 5 mM β-Me). After 1 hour on ice with gentle agitation, the beads were spun down
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by centrifugation (1 minute at 600 g) and the supernatant was removed. The beads were
then washed with Pull-Down Buffer to remove excess protein. Prey proteins were then
added in excess and allowed to incubate with the immobilized bait for 1 hour on ice with
occasional agitation. Unbound protein was then removed through three washes. Each wash
involved adding 200 μL of Pull-down buffer, agitating the mixture, spinning down the
resin, and removing the supernatant. Finally, bound proteins were stripped from the resin
by adding 50 μL of 1x SDS-PAGE loading buffer and boiled for 5 minutes. The samples
were then subjected to analysis by SDS-PAGE. The proteins were visualized by Coomassie
Brilliant Blue staining.

2.4 Isothermal titration calorimetry
A synthetic 18 amino acid peptide containing ATAD5’s PIP box was purchased
from and purified by the Tufts University Protein Core Faculty (Boston, USA). The
sequence of the peptide was: APPLPSNILDYFRKTSPT. The peptide was then dissolved
in ITC buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5 mM β-Me). The proteins were
thoroughly dialyzed and degassed under vacuum before the experiments were conducted.
Isothermal titration calorimetry (ITC) measurements were either performed on the VP-ITC
calorimeter (GE Healthcare) or the Nano ITC calorimeter (TA Instruments) at 25 oC. The
titration of the peptide into PCNA was performed using the VP-ITC calorimeter. The
peptide (750 μM) was loaded into the syringe and injected into the cell containing 50 μM
PCNA in 60 injections of 5μL. A control experiment was performed by injecting the
peptide into buffer under the same experimental conditions. Experimental traces were
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corrected by subtracting the control measurements, and analyzed using Origin 7
(MicroCal). Binding constants, ΔG, and ΔH were calculated
The titrations of ATAD5_SIM into UAF1_SLD2 and UAF1_SLD2M were
performed using the Nano ITC calorimeter. ATAD5_SIM (1 mM) was titrated into a cell
containing 100 μM of UAF1_SLD2 in 25 2 μL injections following an initial 0.5 μL
injection. Control experiments were performed by injecting the peptide into buffer under
the same experimental conditions. Experimental traces were corrected by subtracting the
control measurements, and analyzed using NanoAnalyze (TA Instruments). Binding
constants, ΔG, and ΔH were calculated by fitting the integrated titration data to an
independent binding model.

2.4 Yeast two-hybrid assays
The yeast strain used was PJ69-4A and has the genotypes as described (49). Human
PCNA was recombinantly expressed with the binding domain of the GAL4 by the
integrative vector pASI. Native and mutant N-terminal ATAD5 containing the PIP-box
was recombinantly expressed with the activating domain of GAL4 using the pACT2 vector.
Yeast cells were sequentially transformed using the LiAc method (50) with the bait plasmid
and then the prey plasmid. Selection of the cells containing both the bait and prey plasmids
was carried out on media lacking tryptophan and leucine. Positive interactions were scored
by growth on medium lacking histidine or histidine and adenine.
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2.5 Crystallization
2.5.1 Crystal screening and optimization
Proteins used for crystallization condition screening were either freshly purified or
subjected to size exclusion chromatography. Flash-frozen protein stored at -80 oC was
thawed and loaded onto a SuperdexS200 10/300 GL equilibrated with ITC Buffer. Eluted
protein was then diluted or concentrated for use in crystallization experiments.
Protein complexes were made prior to setting up crystallization trials. PCNA at a
concentration of 1 mg/ml was mixed with 2 molar excess of the synthetic peptide derived
from ATAD5 used in ITC experiments. The protein solution was then left to incubate for
1 hour at room temperature before being concentrated to 6 mg/mL. The ATAD_SIMUAF1_SLD2 complex was collected after ITC experiments were performed and was
concentrated to a concentration of 9 mg/mL. The approximate ratio of ATAD5_SIM to
UAF1_SLD2 is 3:1.
Crystal screening was carried out using both the hanging drop and sitting drop
vapour diffusion method with various commercially available and in-house crystallization
kits. The kits used to screen both complexes included: Hampton Research: Crystal Screen
kit 1, Crystal Screen kit 2, Natrix, and PEG/Ion Kit and Wizard Classic Crystallization
Screen Kit 1, 2, 3, and 4. In addition to the kits mentioned, the peptide-PCNA complex
was also screened with: JSGC+ Crystal Screen, Molecular Dimensions: Midas Crystal
Screen Kit and in-house PEG/Ion screens with varying PEG molecular weights. 1 μL of
protein complex was mixed with 1 μL of the well solution and incubated over a reservoir
of the same well solution.
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After hits were observed, optimization of crystallization conditions was carried out.
Crystals were grown at varying precipitant concentrations and microseeding was employed
in order to improve the shape of crystals. A seed solution was prepared by bead-beating
harvested crystals suspended in mother liquor and added to fresh drops. Additives were
also screened using Hampton Research: Optimization Screen Kit, following the
manufacturer’s suggested protocol.

2.5.2 Data collection and refinement
Crystals were initially screened at the home-source to identify highly diffracting
crystals for data collection. Several crystals were frozen in liquid nitrogen during the
screening process. Highly diffracting crystals were sent to the Canadian Light Source
(Saskatchewan, Canada) for data collection at the CMCF-081D beam line.
The crystal structure was solved using iMOSFLM (51) and the CCP4 program suite
(52). The reflection images were integrated using iMOSFLM and scaled using SCALA and
CTRUNCATE (53, 54). Initial phases were obtained by molecular replacement using
3VKK as a search model in PHASER (55). An initial rigid body refinement was carried
out by RefMac (56) followed by successive rounds of structure building with COOT (57)
and restrained refinements using RefMac. Non-crystallographic symmetry was applied
throughout the refinement process.
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CHAPTER 3: RESULTS I INTERACTION BETWEEN ATAD5 AND PCNA
3.1 Cloning of plasmids
A variety of plasmids were generated in this study to assess the interactions between
ATAD5, PCNA, and UAF1. A summary of the plasmids used and generated is presented
in Tables 2 and 3. All of the plasmids used were confirmed to be correct using DNA
sequencing.
Subcloning was used to generate the plasmids for the yeast two-hybrid studies.
Insert DNA was amplified by PCR and digested with the appropriate restriction
endonucleases and ligated into either pASI or pACT2. The pASI and pACT2 vectors
encode for fusion proteins between the protein of interest and the binding domain and
activating domain of Gal4 respectively.
PIPE cloning was used to generate the plasmids for expression and purification of
ATAD5’s SIM and UAF1’s second SLD (SLD2). The primers used to amplify the insert
(by PCR) added a sequence of nucleotides on each end, complementary to the ends on the
vector. This technique uses the cell’s DNA repair machinery to ligate the plasmid. The
plasmids pMCSG9 and pMCSG10 encode the protein of interest fused to the C-terminal
of MBP and GST respectfully. MBP and GST are both tagged with an N-terminal polyHis tag and contain a TEV cut site at the C-terminal.
The mutation made to the plasmids containing ATAD’s PIP box motif and UAF1’s
SLD2 was achieved by overlap extension PCR. The key PIP box motifs of ATAD5 (I62,
Y65 and F66) were all mutated to Ala using the primers indicated in Table 2. Yang et al.
(2011) reported that a K595E mutation in UAF1 would significantly reduce the ability of
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UAF1 to bind to ATAD5, so this mutation was also used in this study using the primers
indicated in Table 3 (43).

3.2 Purification of proteins
3.2.1 Purification of PCNA
Human PCNA was expressed in E. coli and purified to near homogeneity (Figure
6). Following cell lysis, the sample was clarified using high-speed centrifugation for 15
min at 7000 g. The supernatant was then applied onto prepacked HiTrap Q columns for
anion exchange chromatography (Figure 6A). The protein was eluted from the column
using an increasing gradient of ionic strength. The protein was further purified by heparin
affinity chromatography (Figure 6B). The fractions containing PCNA from anion exchange
chromatography was diluted to reduce the concentration of NaCl before being loaded onto
HiTrap Heparin columns. The protein was again eluted from the column using a gradient
of increasing ionic strength. PCNA was still not sufficiently pure, so the sample was
subjected to mix mode chromatography via ceramic hydroxyapatite (Figure 6C).
Hydroxyapatite chromatography has unique separation properties and can sometimes
separate proteins shown as homogeneous by other chromatographic or electrophoretic
techniques (58). The sample was applied to a 12 mL column and eluted using an increasing
gradient of potassium phosphate. The final low molecular weight contaminants were
removed by size exclusion chromatography (Figure 6D), as PCNA is significantly larger
in solution (as a trimer). Typically, 5 grams of cell paste yielded 25mg of protein. SDSPAGE analysis shows that this protein is suitable for biochemical and structural studies.
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A

C

B

D

Figure 6. Purification of human proliferating cell nuclear antigen (PCNA) (28.7 kDa).
SDS-PAGE analysis after each stage of chromatography. Blue arrows indicate the band of
interest. A) Anion exchange chromatography using HiTrap Q columns. Cell lysate, soluble
protein, flow-through, and eluted fractions are indicated. Fractions in blue box were
pooled. B) Eluted fractions from Heparin affinity chromatography. Fractions 4-6 were
pooled. C) Eluted fractions from hydroxyapatite chromatography. D) Peak fraction of
PCNA after size exclusion chromatography. PCNA is near homogeneity.
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Despite having a predicted molecular weight of 28.7 kDa, individual PCNA
monomers runs at about 34-35 kDa on a 15% SDS-PAGE gel. Gulbis et al. 1996 had
previously reported that human PCNA runs at a higher apparent molecular weight (47).
PCNA from other organisms such as Schizoscaccharomyces pombe and tomatoes have also
been reported to run higher than their expected molecular weight (59, 60).

3.2.2 Purification of GST-fusion proteins
The GST-fusion proteins (GST-p21, GST-ATAD5_PIP and GST-ATAD5_PIPM)
were expressed in E. coli following the same growth and induction parameters. The vector
(pMCSG10) that encodes the recombinant proteins includes a poly-his tag in the N terminal
of GST, allowing IMAC to be utilized as the first purification step. Figure 7A shows a
representative purification of GST-ATAD5_PIPM.
The proteins were purified to near homogeneity after IMAC and anion exchange
chromatography. All of the proteins were soluble following cell lysis. Clarified lysate was
loaded onto 5 mL prepacked cOmplete His-tag purification columns (Roche). After a wash
with a low concentration of imidazole, the remaining proteins were eluted using a high
concentration of imidazole. The eluted sample was then diluted to reduce the NaCl
concentration and loaded onto HiTrap Q HP columns (GE Healthcare) for anion exchange
chromatography. The protein was then eluted using an increasing gradient of ionic strength.
Typically, 10 mg of protein was obtained from 0.5 L cultures.
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Figure 7. Purification of GST-fusion proteins. Purification of ATAD5_PIPM as a
representative purification of GST-fusion proteins. A) SDS-PAGE analysis of the cell
lysate and soluble fraction. The sample was applied to two cOmplete His-tag purification
columns, washed with 10mM imidazole and eluted with 300mM imidazole. Following
IMAC, sample was subjected to anion exchange chromatography via HiTrap Q HP column.
Protein was eluted using increasing ionic strength. B) SDS-PAGE analysis of all GST and
GST-fusion proteins used in pulldowns. GST-p21 (30.4 kDa), GST-ATAD5_PIP (31.2
kDa), and GST-ATAD5_PIPM (31.1 kDa) ran close to their expected molecular weights.
The apparent molecular weight of GST (28.3 kDa) and PCNA (28.7 kDa) were slightly
higher than expected.
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The GST protein to be used as negative controls for the affinity pull-downs were
purified from the cleavage products of tagged protein with TEV protease. Both the GST
and TEV protease contained the poly-His tag, so GST affinity chromatography was used
to separate them. GST and TEV protease was eluted from the IMAC columns after the
cleaved protein of interest was removed. The sample was directly loaded onto a GSTrap
HP (GE Healthcare) and eluted with a buffer containing 10 mM of reduced glutathione.
Typically, 5 mg of GST was obtained from the digestion of 7 mg of GST-p21.
These proteins were resolved close to their predicted molecular weights during
SDS-PAGE analysis and are of sufficient quality to be used in biochemical assays (Figure
7B). GST-p21 (30.4 kDa), GST-ATAD5_PIP (31.2 kDa), and GST-ATAD5_PIPM (31.3
kDa) ran close to their expected molecular weights. The apparent molecular weight of GST
(28.3 kDa) was slightly higher than expected.

3.2 GST Pull-down assays
Work by a previous student showed that the identified putative PIP box in
ATAD5’s N-terminal was able to bind to PCNA, and that mutation of these residues
abolished the binding. The GST pull-down assay was replicated to confirm the findings. In
brief, GST-bound proteins (bait) were incubated with glutathione agarose resin and
allowed to bind. Unbound protein was then washed off and PCNA (prey) was added to the
resin in excess. After several rounds of washing, only the protein that interacts with the
bait remain. These proteins were eluted from the resin and analyzed using SDS-PAGE on
a 15% polyacrylamide gel (Figure 8).
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Figure 8. Pull-down assay showing the interaction between ATAD’s PIP box and PCNA.
Excess GST or GST-fused protein was immobilized onto glutathione resin. Unbound
protein was then washed off and PCNA (prey) was added to the resin in 2 molar excess.
After several rounds of washing, bound protein were eluted from the resin and analyzed by
SDS-PAGE on a 15% polyacrylamide gel. Proteins used in each reaction is shown above
by a “+”, PCNA is indicated by arrows.
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PCNA was observed to co-elute with the native ATAD5 PIP box along with the
positive control using the PIP box from p21. The intensity of the PCNA band was
significantly lower in the lane containing ATAD5 compared to the lane containing p21.
This suggests that the interaction between the PIP box of ATAD5 is weaker than that of
P21 with PCNA. Mutation of the two aromatic residues (Tyr65 and Phe66) to Ala abolishes
the interaction, as PCNA not present in the eluted proteins (Figure 7).
From the Pull-down experiment, we can conclude that the putative PIP box from
ATAD5 interacts with PCNA. Also, this experiment demonstrates that the two aromatic
residues of this PIP box is important for binding. Therefore, we can infer that the binding
mode of this PIP box to PCNA is similar to that of canonical PIP boxes.

3.3 Yeast two-hybrid assays
To confirm the results of the GST pull-down assays, the interaction between the Nterminal of ATAD5 containing the PIP box with PCNA was analyzed in a yeast two-hybrid
system. The two-hybrid system takes advantage of a transcriptional activator that has two
separable functions: one to bind to a specific region of DNA, and the second, to increase
the frequency with which transcription is initiated on an adjacent gene (Figure 9A) (61).
The binding domain (BD) and activating domain (AD) of the transcriptional activator Gal4
is encoded separately by the pASI and pACT2 vectors fused to proteins of interest (62).
The ability to synthesize Leu and Trp is conferred by pASI and pACT2 respectlvely. The
yeast stain that is used in this study (PJ69-4A), will express β-galactosidase and be able to
synthesize His and Ade upon activation of the reporter genes by Gal4 (49).
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PJ69-4A yeast cells were sequentially transformed with plasmids made from the
pASI vector and then the pACT2 vector. PJ69-4A cells were initially transformed using
the LiAc/single-stranded carrier DNA/PEG method with plasmids made with the pASI
vector and plated on selective media lacking Trp. Colonies were picked for each plasmid
and then subsequently transformed with plasmids made with the pACT2 vector. Cotransformed cells were selected by their ability to grow on selective media lacking both
Trp and Leu.
Binding of the N-terminal 250 amino acid residues of ATAD5 and PCNA was
assessed by spot plating co-transformed cells on increasingly selective media.
Transcription of the reporter genes responsible for His and Ade synthesis will allow the
cells to survive on media without these amino acid residues. Cells transformed with both
pASI-PCNA and pACT2-A250 were able to grow on plates lacking Trp, Leu, and His
and/or Ade (Figure 9B). Cells transformed with both pASI-PCNA and pACT2ATAD_N250M (containing mutations to key PIP box residues), were not able to grow on
the plates lacking His and/or Ade (Figure 9B). From these results, we have confirmed that
the putative PIP box is able to interact with PCNA and mutations of the conserved residues
in the PIP box abolishes binding.

3.4 Isothermal titration calorimetry
With the interaction between ATAD5’s PIP box and PCNA confirmed by both GST
pull-down assays and the yeast two-hybrid system, we wanted to characterize the
interaction. The thermodynamic parameters of the interaction were characterized by ITC
using the VP-ITC calorimeter. In ITC, the energy absorbed or given off from a reaction
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Figure 9. Interaction of ATAD5’s N-terminal 250 amino acids with native PCNA in a
yeast two-hybrid system. A) Binding of the two proteins fused to Gal4’s binding domain
and activating domain will start transcription of t. B) PJ694A cells were successively
transformed with the plasmid encoding native human PCNA and then with either the
pACT2 vector, encoding only the AD of Gal4, and pACT2-ATAD5_N250 or pACT2ATAD5_N250M which encodes the N terminal 250 amino acids of ATAD5 or the mutant.
These cells were then spot plated with an initial dilution of 1000x and then serial diluted 4
times on increasing selective media (blue triangles represent dilution).
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between two components is measured and the thermodynamic terms that define the binding
affinity, enthalpy (∆H) and entropy (∆S), can be determined (63).
The binding affinity of ATAD5’s PIP box with PCNA was determined using a
synthetic peptide. The full-length ATAD5 protein is relatively large, comprising of 1844
amino acid residues, with the first ~1000 residues predicted to be disordered. For this
reason, an 18 amino acid residue peptide was synthesized that contained the PIP box of
ATAD5. The flanking sequence of amino acids on both sides of the PIP box were
conserved. The synthetic peptide containing the PIP box of ATAD5 was diluted in ITC
buffer and thoroughly dialyzed. The pH of the peptide sample after dialysis overnight did
not match that of the buffer, so the time of dialysis was extended to 36 hours total. The
peptide was loaded into the syringe and titrated stepwise into the cell containing PCNA. A
control experiment was conducted in which the peptide was titrated into a cell containing
ITC Buffer only (Figure 10A). The control experiment was subtracted from the
experimental traces and fitted to a one-site binding model (Figure 10B-C). The Kd of the
interaction was determined to be 6.17  0.78 M with an n of 0.93 ± 0.01. The
stoichiometry of the reaction is close to 1, meaning that each peptide binds to one
monomer. The H, S and G of the reaction is -2.18 ± 0.04 kcal, 16.5 cal mol-1 K-1 and
-7.01 kcal/mol respectively.
From the ITC data, we determined that the interaction is in the low micromolar
range, each monomer of PCNA is able to bind to one peptide, and that the interaction occurs
under favourable conditions, however it is non-spontaneous.
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Figure 10. Determination of the thermodynamic parameters of the binding between
ATAD5’s PIP box and PCNA. Thoroughly dialyzed peptide (800μM) was titrated stepwise
into the cell in 2.5μL injections at 25oC. Binding thermograms from titration of a synthetic
peptide containing ATAD5’s PIP box into the cell. A) A control experiment was conducted
in which the peptide was titrated into a cell containing ITC Buffer only. B) The peptide
was titrated into a cell containing 40μM of PCNA. C) Replicate of titration described in
(B)
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3.5 Crystallization of PCNA:ATAD5 peptide complex
In order to determine the structural features of the binding between the PIP box of
ATAD5 and PCNA, the x-ray crystal structure was determined. Since ATAD5 is too large
for crystallographic experiments, the 18 amino acid residue peptide from ITC experiments
was used. Crystallization trials were conducted to determine the condition where both
PCNA and the peptide would co-crystalize.

3.5.1 Screening and optimization
Crystallization trials were carried out in order to determine the condition required
to crystalize the protein-peptide complex. PCNA at 1 mg/mL was incubated with the
peptide dissolved in ITC Buffer in 3 molar excess for 1 hour at room temperature. The
protein complex was then concentrated to 6 mg/mL. Both the hanging drop and sitting drop
vapour diffusion techniques were used in the screen. 1 L of the protein complex was
mixed with 1 L of the well solution and suspended over 500 L resovoir of well solution.
The well solutions were from commercial and in-house crystallization kits. In the end over
1000 unique conditions were screened. Many conditions produced crystals, however, they
closely resembled the native crystallization conditions and were rejected. Other conditions
that were identified by the screen included: 2 M ammonium sulphate, citrate pH 5.5, 50 %
PEG 400, 0.1 M sodium acetate/acetic acid pH 4.5, and 30 % PEG 400, 0.2 M calcium
acetate (Figure 11). The condition using 30 % PEG 400 and 0.2 M calcium acetate was
reproducible and produced crystals within 2-3 days so it was chosen for optimization.
Initially, the crystals were not well formed (Figure 11D); however, if PCNA was subjected
to size exclusion chromatography on a Sephadex S200 10/300 GL
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Figure 11. Hits from crystallization trials for complex of PCNA and a synthetic peptide
derived from ATAD5. 1 L of the protein complex was mixed with 1 L of the well
solution and suspended on 500 L of well solution. The well solutions were from
commercial and in-house crystallization kits. 3 hits were observed. A) 2 M ammonium
sulfate, citrate pH 5.5. B) 50% PEG 400, 0.1 M sodium acetate/acetic acid pH 4.5. C) 30%
PEG 400, 0.2 M calcium acetate. D) Crystallization condition from (C) was reproducible.
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column equilibrated with 25 mM HEPES pH 7.5, 150 mM NaCl and 5 mM β-Me prior to
forming the complex, more of the resulting crystals are well-shaped and larger (Figure
12A). These crystals did not diffract past 6 Å however.
Both the micro seeding and streak seeding techniques were used in an attempt to
produce better diffracting crystals. Microseeding appeared to be more effective, however,
large crystal showers were observed (Figure 12B). Different precipitant concentrations
were then screened in combination with microseeding. Larger well-shaped crystals were
observed at 25 % PEG 400 (Figure 12C). Since low molecular weight PEGs are suitable
cryoprotectants, these crystals were directly frozen in liquid nitrogen to be used in x-ray
diffraction experiments. Despite lacking any visual imperfections, the crystals only
diffracted to a maximum of 4.5 Å at the Canadian Light Source. After multiple rounds of
crystallization without high-diffracting crystals, additives were screened from the
Optimization Screen Kit (Hampton Research) following the manufacturer’s instructions.
Many additives produced the same well-shaped crystals, all corresponding to metal cations.
The largest, well-shaped crystals appeared with the addition of MgCl2. Finally, a crystal of
the protein complex was grown in 25 % PEG 400, 0.2 M calcium acetate, and 10 mM
MgCl2 with microseeding (Figure 11D). These crystals diffracted with higher resolution,
up to 2.2 Å on the CMCF-081D beam line at the Canadian Light Source.
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Figure 12. Optimization of the crystallization condition for the crystallization of
PCNA/Peptide complex. The initial condition of 30% PEG 400, 0.2M calcium acetate was
used. 2 L of the protein complex was mixed with 2 L of the well solution and suspended
over 500 L of well solution. A) Use of protein refreshed via size exclusion
chromatography pre-equilibrated in ITC Buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 5
mM β-Me) produced larger well shaped crystals. B) Protein crystals from A were used to
make a seed stock for microseeding. 0.2 L of this stock was added to drops. Many small
well-formed crystals grew. C) Concentration of PEG 400 was reduced to 25 %. This
produced larger crystals, however none of the crystals diffracted past 4.5 Å. D) Final drop
was spiked with MgCl2 to a final concentration of 10 mM. Resulting crystals were large
and diffracted to high resolution.
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3.5.2 Structure determination of PCNA:ATAD5 peptide complex
The highest diffracting dataset was used to solve the structure of the complex
between PCNA and the synthetic peptide containing ATAD5’s PIP box. First, the
collection of refraction images was processed in iMOSFLM (51). From previous datasets
obtained from the home source, the space group was thought to be h6, however, the recent
high-resolution dataset showed that the space group was either P3121 or P3122. The cell
parameters were consistent with the previous low-resolution dataset, with two axis of the
same length (a, b = 83.7 Å) and one significantly longer axis (c = 209.6 Å). Integration of
the data set was disrupted by refraction images that contained large spots. Removal of these
images from the dataset allowed for the integration of the remaining dataset into one .mtz
file. The data was then scaled to a resolution of 2.2 Å with CTRUNCATE and SCALA
(53). Initial phases were obtained by molecular replacement in PHASER using monomeric
human PCNA structure (PDB ID: 3VKX) as a search model (55). Here, the space group
was determined to be P3121, with three PCNA monomers in the asymmetric unit cell. After
an initial rigid body refinement in RefMac, successive rounds of structure building in
COOT and smooth body refinements with non-crystallographic symmetry restraints were
carried out (56, 57). Un-modeled blobs around the hydrophobic region of PCNA where
initially filled with Ala before mutation of the residues to correspond with the peptide
sequence. The data collection and refinement statistics are summarized in Table 4.
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Table 4. Data collection and refinement statistics for the structure of PCNA with a
synthetic peptide derived from ATAD5.*
Data collection
Space group
Cell dimensions
a, b, c (Å)

P3121

 ()

90, 90, 120
50.0-2.20(2.32-2.20)
0.10(0.63)
10.9 (3.4)
99.9 (100.0)
8.5 (8.9)

Resolution (Å)
Rsym or Rmerge
I/I

Completeness (%)
Redundancy

83.7, 83.7, 209.6

Refinement
Resolution (Å)
No. reflections
Rwork/ Rfree
No. atoms
Protein
Peptide
Mg2+/PEG
Water
B-factors
Protein
Peptide
Mg2+/PEG
Water
R.m.s deviations
Bond lengths (Å)
Bond angles (º)

50.0-2.20
44, 086
22.5/27.6
5852
289
2/14
228
45.8
66.1
58.9/47.5
45.9
0.010
1.53

*Values in parenthesis are for the highest-resolution shell. Crystal data was collected on
the CMCF-081D beam line at the Canadian Light Source (Saskatchewan, ON). The data
was integrated using iMOSFLM and scaled with SCALA and CTRUNCATE. Molecular
replacement was performed using PHASER with the search model 3VKX. Successive
rounds of refinement and model building was done using REFMAC and Coot.
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3.5.3 PCNA:ATAD5 peptide complex structure
The crystal structure was solved by molecular replacement to a resolution of 2.20
Å. The PCNA structure has three subunits that are arranged head-to-tail (Figure 13C). The
quaternary structure is of a toroid, as N- and C-terminal regions form subunit-subunit
contacts. The monomers are structurally similar, with RMSD values between subunits
ranging from 0.397 to 0.559 Å over 248 residues and surface areas ranging from 12318 to
12737 Å2. The PCNA trimer has a pseudo 6-fold symmetry, with two similar domains in
each subunit. Each domain consists of 2 α-helices and 9 β-strands. The trimer therefore
consists of 12 α-helices and 54 β-strands in total. Each monomer was modelled
unambiguously from residues 1-256, however there was poor density for the five Cterminal residues and a loop region in two of the monomers. Similar regions of missing
density have been reported in other PCNA structures as well (64–66).
One peptide molecule binds to each of the three PCNA monomers in the
asymmetric unit. Binding the peptide does require or induce large-scale structural
rearrangements of PCNA as there is little global change upon peptide binding (Figure 14).
The peptide-bound PCNA structure is structurally similar to the apo PCNA structure
(1VYM), with a RMSD of 0.75Å over 248 residues. According to the x-ray structure
model, 9 to 13 of the 18 amino acids in the peptide were resolved in each subunit.
The three peptides are also structurally similar, with RMSD values between 0.37 to
0.51 Å over 66 atoms. The surface areas of the peptide range from 1395 to 1729 Å2 with
the contact surface area ranging from 562 to 673 Å2 (approximately 40 %). Figure 13D
shows the electron density (2Fo - Fc) map contoured to 1.2 Å around the peptide with
respect to PCNA.
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Figure 13. Structure of PCNA co-crystalized with a synthetic peptide derived from
ATAD5. A) Crystal mounted onto 0.2-0.3mm loop and directly frozen in liquid nitrogen.
B) Diffraction image taken of crystal at CMCF-081D beam line at the Canadian Light
Source. Crystals diffracted to 2.2Å and belonged to the space group P3121 with unit cell
dimensions of a, b = 83.7 Å and c = 209.6 Å. C) Cartoon representation of complex
structure with transparent surface. One peptide (yellow) binds to each monomer of PCNA
(purple). D) 11-13 residues of the peptide were resolved in the final structure. 2Fo - Fc map
of peptide represented as sticks (yellow) is shown and contoured to 1.2 Å.
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Figure 14. Binding of peptide does not induce significant conformational changes in
PCNA. Cartoon representation of the two structures superimposed is shown. The co-crystal
structure of PCNA with the ATAD5 peptide (purple) has a high global similarity to the apo
form of PCNA (grey; PDB ID: 1VYM) when superimposed with a RMSD 0.75Å over 248
residues.
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The binding of the peptide containing ATAD5’S PIP box to PCNA is topologically
conserved with respect to proteins with canonical PIP boxes (65, 67–70). There are two
main interacting regions on the peptide. The first is the PIP box region which forms a 3 10
-helix with the hydrophobic residue pointing towards the minor hydrophobic groove of
PCNA and the two aromatic residues pointing towards the major hydrophobic pocket
(Figure 15A). The second is near the C-terminal region where Arg 67 and Thr 69 form
hydrogen bonds with Gln 125 and Gly 127 of the IDCL (Figure 15B). The C-terminal of
the peptide points toward the bulk solvent however, instead of interacting with amino acid
residues along the IDCL.

54

A

B

Figure 15. ATAD5 binds to the hydrophobic pocket of PCNA. A) Surface representation
of PCNA with hydrophobic areas coloured yellow and the peptide (teal) represented as
ribbon. PIP box residues are represented as sticks. The side chains of Ile 62 faces the minor
hydrophobic groove and the side chains of Tyr 65 and Phe 66 point toward the major
hydrophobic pocket. B) Scheme of interactions between the synthetic peptide derived from
ATAD5 and PCNA. Indicated are the residues (framed for PCNA), bound water (blue
circles, hydrogen bonds (dotted lines), and non-bonded interactions (black arrows). The
helix is shaded light blue.
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CHAPTER 4: RESULTS II UAF1-ATAD5 INTERACTION
After characterizing the interaction between ATAD5’s PIP box and PCNA, we
wanted to explore ATAD5’s interactions with UAF1. ATAD5 contains a SIM which is
thought to interact with a SLD on the C-terminal of UAF1. In order to study this interaction,
the genes encoding the domains of interest from the appropriate proteins were cloned into
expression vectors. A mutation (K595E) was made to UAF1’s SLD that has been
previously shown to reduce its binding to ATAD5. These proteins were then subsequently
expressed and used for biochemical characterization.

4.1 Expression and purification of ATAD5_SIM, UAF1_SLD2 and UAF1_SLD2M
ATAD5_SIM, UAF1_SLD2 and UAF1_SLD2M were expressed in E. coli
following the same growth and induction parameters. pMCSG10 encodes a N-terminally
fused MBP tag to the protein of interest with a TEV cut site in between. The MBP tag
contains a poly-his tag at its N-terminal allowing IMAC to be used in the purification of
the protein of interest.
All of the proteins were soluble and purified to near homogeneity after two rounds
of IMAC and anion exchange chromatography. The purification of UAF1_SLD2 is shown
in figure 16A-C as a representative purification. Clarified lysate was subjected to IMAC
using 5 mL prepacked cOmplete His-tag purification columns (Roche). Following elution,
TEV protease was added to the sample at a 1:40 ratio and the sample was left to dialyze
overnight in buffer suitable for TEV protease activity (25 mM Tris pH 7.5, 150 mM NaCl,
0.5 mM EDTA, 7 mM β-Me). The sample was then passed through the cOmplete His-tag
purification columns (Roche), untagged proteins flowed through the column, leaving the
His-tagged TEV protease and MBP behind. The flow-through sample was then diluted
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Figure 16. Representative purification of tagged protein and subsequent tag cleavage by
TEV protease. UAF1_SLD was expressed in e. coli as a MBP-fusion protein. A) SDSPAGE analysis of the cell lysate and soluble fraction, as well as the first IMAC step. The
eluted proteins were pooled. B) SDS-PAGE analysis of the second IMAC step. After the
first IMAC step, TEV protease was added and the sample was left to dialyze against ITC
buffer (Table 1). SDS-PAGE analysis shows that the cleavage was complete. MBP tag and
TEV were removed through another round of IMAC. C) The flow flow-through was
subjected to anion exchange chromatography. Fraction 2 was collected and used for
biochemical analysis. D) SDS-PAGE analysis of all GST and GST-fusion proteins used in
pulldowns. GST-ATAD_SIM (36.1 kDa) was resolved on the gel close to the predicted
molecular weight. ATAD_SIM (7.8 kDa), UAF1_SLD2 (13.7 kDa) and UAF1_SLD2M
(13.7 kDa) were resolved at a slightly higher molecular weight than predicted.
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until an appropriate NaCl concentration was reached for anion exchange chromatograph.
Typically, 6 mg of protein was obtained from 0.5 L of culture. These proteins were resolved
close to their predicted molecular weights during SDS-PAGE analysis and are of sufficient
quality to be used in biochemical assays (Figure 16D).
GST-ATAD5_SIM was purified as per “3.1.2 Expression and Purification of GST-fusion
proteins”. To obtain ATAD5_SIM, GST-ATAD5_SIM was digested with His-tagged TEV
at a 1:40 ratio for 2 hours at room temperature followed by 16 hours at 4 oC. The sample
was then passed through pre-equilibrated cOmplete His-tag purification columns (Roche)
to remove the His-tagged TEV protease and GST. ATAD5_SIM was then determined to
be of sufficient quality by SDS-PAGE and stored at -80oC for future use (Figure 16D).

4.2 GST pull-down assay
To determine whether or not the SIM on ATAD5 interacts to the second SLD of
UAF1, a pull-down assay was performed. A positive and negative control was included.
The positive control consisted of GST-p21 and PCNA, which is known to interact with
each other and has been previously demonstrated (Section 3.2). The negative control
consisted of GST and UAF1_SLD2, this allowed us to determine if there are any nonspecific interactions between these two proteins. GST-ATAD5_SIM, GST, and GST-p21
was immobilized to the glutathione agarose resin. Excess prey proteins were then added to
the immobilized bait proteins. PCNA was added to GST-p21, UAF1_SLD2 was added to
GST-ATAD5_SIM and GST and UAF1_SLD2M was added to GST-ATAD5_SIM. After
washing off the excess proteins, the bound proteins were eluted and analyzed by SDS-
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Figure 17. Interaction between ATAD5’s SIM and UAF1’s SLD2 cannot be detected by
GST pull-down assay. Excess GST or GST-fused protein was immobilized onto 15 µL of
glutathione resin. Unbound protein was then washed off and prey proteins were added in
excess. After several rounds of washing, bound protein were eluted from the resin and
analyzed by SDS-PAGE on a 15 % polyacrylamide gel. GST-p21 and PCNA were used as
a positive control for the assay. No UAF1_SLD2 band was detected in the output.
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PAGE. SDS-PAGE analysis of the elution products did not reveal any binding to occur
between UAF1_SLD2 and GST-ATAD5_SIM. Neither UAF1_SLD2 or UAF1_SLD2M
were present on the output lanes of the 15 % polyacrylamide gel (Figure 17). The positive
and negative controls both worked however. From these results, we can speculate that the
binding between these two polypeptides are too weak to be determined by this technique
or that they don’t interact.

4.3 Isothermal titration calorimetry
Despite not seeing an interaction between the SIM and SLD2 of ATAD5 and UAF1
respectively, ITC was used in order to confirm the interaction between these two proteins
and to characterize the binding affinity. A previous study by Yang et al. (2011)
demonstrated that UAF1 interacts with ATAD5, and loses its ability to interact upon
deletion of the second SLD domain. Yang et al. (2011) detected the proteins using a co-IP
assay in transfected mammalian cells, where intracellular concentrations of the proteins are
relatively high (43). The pull-down assay performed may not have been able to detect the
interaction due to the relatively low concentrations of proteins. Also, the pull-down assay
may not be sensitive enough to detect weak protein interactions. Due to the potentially low
binding affinity of the reaction, a more sensitive method is required. ITC was chosen as
interactions in a wide range of binding affinities can be assessed, from milimolar to
nanomolar (10-2 to 10-9 M).
ATAD5_SIM was titrated into UAF1_SLD or UAF1_SLDM in order to determine
if binding between the two proteins occur and to characterize the thermodynamic
parameters of the interaction. High concentrations were used since no interaction was
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detected from the pull-down experiments. 1 mM of ATAD5_SIM was loaded in the syringe
of the NanoITC Calorimeter (TA Instruments) and titrated into the cell containing 100 M
of UAF1_SLD or UAF1_SLDM at 25 oC. Due to the use of highly concentrated proteins,
two control experiments were conducted: the first being buffer titrated into the cell
containing 100 M of UAF1_SLD and the second being 1 mM of ATAD5_SIM titrated
into buffer. The titration of buffer into the cell with UAF1_SLD did not produce significant
heats, however, the titration of ATAD5_SIM into buffer did (Figure 18A-B). The
experimental traces were corrected by subtracting the control measurements and analyzed
by NanoAnalyze (TA Instruments) using an independent binding model (Figure 18C-D).
ITC measurement of the ATAD5_SIM and UAF1_SLD reaction showed a Kd of of 19.10
± 6.48 M, n = 0.442 ± 0.076, ∆H of -26.62 ± 7.12 kJ/mol, and a ∆S of -4.025 J/mol·K.
ITC measurement of the ATAD5_SIM and UAF1_SLDM reaction showed a Kd of 77.82
± 11.24 M, n = 0.142 ± 0.05, ∆H of -99.95 ± 23.4 kJ/mol, and a ∆S of -256.6 J/mol·K.
From the ITC experiments, it is evident that there is an interaction between the SIM
of ATAD5 and the second SLD of UAF1. Mutation of a lysine (K595E) of UAF1 in the
SLD2 domain reduced the binding affinity approximately 4-fold.
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Figure 18. Determination of the thermodynamic parameters of the binding between
ATAD5_SIM and UAF1_SLD2. Thermograms and experimental traces of various
titrations. Buffers of proteins were exchanged by size exclusion chromatography prior to
experiments. Titrations were performed stepwise in 2 μL injections followed by an initial
injection of 0.48 μL at 25 oC. A) Titration of ATAD5_SIM with buffer. B) Titration of
buffer with UAF1_SLD2. C) Titration of ATAD5_SIM with UAF1_SLD2. D) Titration of
ATAD5_SIM with UAF1_SLD2M.
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4.2 Crystallography
Since we have established that the SIM from ATAD5 interacts with UAF1’s SLD2, we
wanted to characterize the structural features of the interaction, to see if it is indeed similar
to the interaction between SUMO and the SUMO-interacting motif. In order to do this,
crystallization trials were initiated to determine the crystallization condition for this
complex. Protein from the ITC experiments were concentrated to 9 mg/mL and used in
crystallization trials. The final molar ratio of ATAD5_SIM to UAF1_SLD2 was
approximately 3:1. Aside from sample preparation, screening was carried out as before
using a limited number of commercial crystal screen kits. A hit was observed and
corresponded to the condition: 0.1 M HEPES pH 7.5, PEG 8000, 8 % ethylene glycol. One
solitary hexagonal plate was observed in this condition 2 weeks after the screen was set up
(Figure 19A). Longer incubation of the crystal did not encourage visible crystal growth.
The crystallization of the ATAD5_SIM:UAF1_SLD2 complex in this condition could not
be reproduced. Varying the concentrations of the components (precipitant, buffer pH, or
protein concentration) did not produce any crystals either. IZIT dye (Hampton Research)
was used in order to determine whether or not the crystal was protein, as crushing of the
crystal was undesirable. The dye was able to permeate through the solvent channels of the
crystal, indicating it is made of protein (Figure 19B). The crystal was mounted onto a 0.05
mm loop and streaked through the mother liquor spiked with an additional 50 % ethylene
glycol and frozen in liquid nitrogen. Unfortunately, no diffraction was seen on the CMCF081D beam line at the Canadian Light Source (figure 19D).
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Figure 19. Crystal of the complex between ATAD5_SIM and UAF1_SLD2. A) The crystal
was grown at 18 oC from protein complex at 9 mg/mL at a ratio of 1:3 (SLD2 to SIM) in
0.1 M HEPES pH 7.5, PEG8000, 8% ethylene glycol 3 weeks after initial set up. The
crystal is indicated by a blue arrow. B) Attempts to reproduce the crystal were unsuccessful
so it was tested with IZIT dye. Crystal took up the dye and was stained blue. C) The crystal
was mounted onto a 0.05 mm loop and treated with 30 % ethylene glycol before flash
frozen in liquid nitrogen. D) Diffraction image from the crystal. No diffraction pattern was
observed other than from ice.
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CHAPTER 5: DISCUSSION
5.1 ATAD5 contains a PIP box motif
In this work, we have demonstrated that ATAD5 contains a PIP box motif that
mediates its interaction with PCNA. Previous reports have suggested that PCNA may
interact with ATAD5, however, any binding had yet to be investigated. We have identified
a PIP box in the N-terminal of ATAD5 through sequence analysis that resembles that of
the Y-family polymerases and rfc1 of the RFC complex. ATAD5’s PIP box contains a Pro
at position 1 of the consensus sequence instead of the canonical Gln and an Ile, Tyr, and
Phe at positions 4, 7, and 8.
We determined that this putative PIP box motif was able to bind to PCNA using a
GST pull-down assay (Section 3.2) and a yeast two-hybrid system. GST-ATAD5_PIP coeluted with PCNA in the assay. The amount of PCNA that co-eluted with GST-APIP
compared to GST-p21 was significantly lower (Figure 7). This suggests that the interaction
between PCNA and the PIP box from ATAD5 is weaker than that of p21. To confirm the
results of the pull-down assay, the interaction was studied in a yeast two-hybrid system.
Yeast cells were transformed with plasmids expressing recombinant protein fused to either
the BD or AD of the transcriptional activator protein Gal4 and spot plated to determine the
phenotype of the resultant yeast. Consistent with the previous results, yeast cells cotransformed with the native N-terminal 250 amino acids of ATAD5 and PCNA showed the
phenotype indicative of interaction and were able to grow on the desired selection media.
Mutation of the conserved PIP box residues (at position 4, 7, and 8) to Ala abolishes
the interaction between ATAD5 and PCNA in both the GST pull-down assays, as well as
the yeast two-hybrid system. The result of the experiments with the mutants agrees with
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what is known about PIP box/PCNA interactions. Without the proteins that make up the
“hydrophobic plug”, the interactions that stabilize the PIP box in PCNA’s hydrophobic
pocket cannot occur.
Taken together, our results show that the putative PIP box identified interacts with
PCNA, and that the conserved PIP box residues are important for interaction.

5.2 Comparing ATAD5’s PIP box to other known structures
5.2.1 ATAD5 does not possess a canonical PIP box
A reason that ATAD5’s PIP box was yet to be identified may be that it does not
completely conform to the canonical consensus sequence (Figure 2). In the place of a Gln,
there is a Pro at position 1 of the motif. There have been relatively few non-canonical PIP
boxes studied where the residue at position 1 was not Gln. Many of the Y-family
polymerases have non-canonical PIP Boxes and contain either a Lys (polymerase  and
polymerase ) or a Met (polymerase ) at this position (65). The Gln from other PIP box
motifs interact with the main chain carbonyl of A252 on PCNA, and a well-ordered water
molecule bridges the O of Gln and the amide-nitrogen atom of A208 at the C-terminal end
of the F2 strand of PCNA. Kroker et al. (2015) identified it as the second highest
contributor to p21’s high binding affinity in an in silico alanine scanning experiment (67).
In contrast, the Pro at position 1 of ATAD5’s PIP box does not form any hydrogen bonds
with surrounding residues or water molecules. Previous experiments where the residue at
position 1 is mutated to Gln to conform to the consensus sequence, the binding affinity
between the peptide and PCNA increased 4-fold (65). The presence of a Pro instead of a
Gln may contribute to the lower binding affinity observed between ATAD5’s PIP box and
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PCNA. Proline is a proteinogenic amino acid with a secondary amine, so the α-amino group
is part of the side chain. This property usually causes disruption to the secondary structure
of proteins.
Interestingly, most of the polymerases that are involved in TLS do not have
canonical PIP boxes and have alternative amino acids at position 1. ATAD5, which is
responsible for deubiquitinating of PCNA and controlling retention of TLS polymerases
on the replication fork also does not have the conserved Gln at position 1 either. There is
currently no data to ascertain the significance of why these proteins involved in the DNA
damage tolerance pathways contain non-canonical PIP boxes.

5.2.2 ATAD5’s PIP box binds PCNA in a topologically conserved manner
The binding of ATAD5’s PIP box is topologically conserved, many other crystal
structures of peptides containing PIP boxes derived from other proteins in complex with
PCNA show the formation of the characteristic hydrophobic plug where residues at
position 4, 7, and 8 interacts with the hydrophobic pocket (47, 64, 65). Despite being
predicted to be disordered, ATAD’s PIP box confers a 310 -helix structure when bound to
PCNA. The PIP box forms a “hydrophobic plug” that interacts with a hydrophobic pocket
on PCNA (Figure 15A). Figure 20A shows a superposition of known structures of PIP box
binding with PCNA. As seen in Figure 15A, hydrophobic residue I62 points towards the
minor hydrophobic groove of PCNA and the two aromatic residues (Y65 and F66) point
towards the major hydrophobic pocket.
The three residues at positions 4, 7, and 8 are important for the interaction with
PCNA, and it has been hypothesized that the identities of these residues are responsible for
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F66

Y151
Y65
F150

I62
M147
Q144
P59
Figure 20. Comparison of human PIP box binding to PCNA. A) Cartoon representation of
PCNA monomer (from this study, in gray) and the superposition of PIP boxes after
structural alignment against other structures of PIP box peptides binding to PCNA. Peptide
derived from ATAD5 is shown in yellow, other structures represented in this diagram are:
1U7B (red), 1U76 (orange), 2ZVK (green), 3P87 (cyan), 4RJF (blue), 4ZTD (purple) and
4D2G (pink). B) Surface representation of PCNA monomer (from this study, in gray) with
cartoon representations of peptides derived from ATAD5 in yellow and p21(PDB ID:
1AXC) in blue. PIP box residues (labelled with respective colours) are represented as
sticks.
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tuning binding affinity (67). Comparing the binding of the hydrophobic residue
from ATAD (our structure) and p21 (PDB ID: 1AXC), p21’s PIP box packs tighter into
the hydrophobic pocket compared to ATAD’s (Figure 20B). In our structure, the nitrogen
from the amine group of the Ile forms a hydrogen bond with His 44 carbonyl group’s
oxygen from PCNA in the two aromatic residues at position 7 and 8 forms many nonbonded contacts with many of the amino acids that make up the hydrophobic pocket of
PCNA. In the p21 structure, a well-ordered water molecule helps stabilizes the interaction
of the peptide with PCNA by forming many non-bonded contacts with the Tyr at position
8. Phe at this position on our structure only forms one hydrogen bond with G127 of PCNA.
The identities of the PIP box residues that form the hydrophobic plug is only one
factor that affects the overall binding affinity of the PIP box peptides to PCNA. Residues
can also interact with PCNA’s IDCL.

5.2.3 ATAD5 peptide’s interaction to the IDCL
The C-terminal of the peptide derived from ATAD5 used in our study does not have
many amino acids that make contacts with the IDCL of PCNA compared to the peptide
from p21. Only three residues are resolved after F66 in the C-terminal in the final structure.
The remaining residues are most likely do not interact with PCNA and are hence too
flexible to be seen in the structure and point toward the bulk solvent. In contrast to the p21
peptide structure, the C-terminal of the ATAD5 peptide does appear to make extensive
contacts with the IDCL. In p21, the C-terminal nine amino acids form a -strand that
interacts with the IDCL. A recent article was published where in silico alanine scanning
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identified two Arg residues four amino acid residues downstream from the last PIP box
residue that contribute to p21’s high binding affinity (71).
The resolved residues that follow the last PIP box residue (RKT) interact with
PCNA’s IDCL. Four hydrogen bonds exist here: Arg forms two hydrogen bonds with Gly
127 between an oxygen from their carboxyl and nitrogen from their amine groups.
Threonine also forms two hydrogen bonds, one between its nitrogen-amine group and an
oxygen from the carboxyl group of Gln 125, and the second between O1 and the nitrogen
amine group of Gly 127. It is interesting that the residues after position 8 form more
hydrogen bonds with the IDCL of PCNA than the aromatic residues in the PIP box.
Therefore, it is important to not only take into consideration the binding of the hydrophobic
pocket but the IDCL as well when designing agents to inhibit PCNA binding.

5.3 UAF1 interacts with ATAD5
Prolonged replication by TLS polymerases may become a source of mutations, so
regulation of their lifespan on the replication machinery is critical. Removal of ubiquitin
from PCNA facilitates the switching from TLS polymerases to regular high-fidelity
polymerases. ATAD5 contains a SIM in its N-terminal domain that recruits the DUB
complex UAF1-USP1. We wanted to characterize this interaction to assess ATAD5’s
ability to act as an adapter between ubiquitinated PCNA and UAF1. ATAD5 may form a
complex with UAF1 that can compete with the binding of Y-family polymerases to
ubiquitinated PCNA.
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5.3.1 UAF1_SLD2/ATAD5_SIM interaction was not detectable in affinity pull-down
assay
The interaction between ATAD5’s SIM and UAF1’s second SLD could not be
detected in our affinity pull-down assays. No interaction was detected as UAF1’s SLD2
did not co-eluted with GST fused to ATAD5’s SIM. There are several reasons for this
occurrence. Firstly, the GST-affinity pull-down technique is more suited for stronger
interactions, weak or transient interactions may not be detected by this method. Secondly,
the cloned portion of the SIM is not sufficient to facilitate interaction, only 39 amino acids
(the SIM was flanked by ten amino acids) were amplified out of ATAD5; this may not be
enough for it to fold correctly. Lastly, Yang et al. (2011) studied this interaction using coIP experiments using extracts from cells transfected with the proteins of interest (where
intercellular concentrations were high) (43). Additional cofactors may be present in the cell
extract that facilitates the binding.

5.3.2 ITC reveals µM binding between UAF1_SLD2 and ATAD5_SIM
Despite not seeing a positive result from the pull-down assays, the interaction
between ATAD5_SIM and UAF1_SLD2 was determined to have a Kd of 19.1 ± 6.48 µM.
ITC experiments can detect a wide range of binding affinities (from nM to mM). With the
assumption that the protein is weak (from the GST pull-down experiments), we used high
concentrations of proteins. ATAD5_SIM was loaded into the syringe and titrated into a
cell containing UAF1_SLD2. The Kd of this reaction was approximately 3-4 fold lower
than the ATAD5 PIP box/PCNA interaction. The binding affinity seen in the ITC
experiments were not completely unexpected. Lee et al. (2010) found that the chromatin-
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bound USP1 level was not changed after ELG1 knockdown and USP1 or UAF1 foci was
not formed in response to DNA damage (72). Mutation of a lysine important for the
interaction between ATAD5 and UAF1 resulted in a 4-fold reduction in binding affinity,
the dissociation constant of this reaction was found to be 77.82 ± 11.24 M. This result
agrees with the observations made by Yang et al. (2011) where they observed a reduction
in ATAD5 binding to UAF1 bearing the same mutation (43).
We were able to determine that UAF1 binds to ATAD5’s SIM in the low µM range.
The binding affinity between these proteins is reduced upon mutation of a lysine on UAF1.
Our experiments contribute to the confirmation that the binding between the SLD2
sequence of UAF1 with ATAD5’s SIM has conserved binding characteristics to known
SUMO/SIM interactions previously described in the literature (73).

5.4 Functional implications
Many proteins interact with PCNA by the way of the PIP box motif. Almost 200
different biological PIP boxes have been proposed from a bioinformatics analysis. From
the data available, not all PIP boxes interact with the same affinity (Table 5). The variations
of the amino acid at each position allows for the “tuning” of the binding affinities, possibly
linking it to the protein’s function (67). What guides the binding of various proteins to
PCNA during different pathways is unclear, as PIP boxes binding to PCNA’s hydrophobic
pocket with low affinity can be displaced those of higher affinity, such as p21’s PIP box
(47).
PCNA-PIP box interactions may not have been optimized for high affinity during
evolution. PCNA is thought to be a “toolbelt” for replication machinery, allowing multiple

Table 5. Summary of PIP box-containing peptides from crystal structures available from the Protein Data Bank (www.pdb.org).
Positions 1, 4, 7 and 8 of the PIP box consensus sequence are bolded.

PDB ID

Author

Peptide Sequence

Kd

Ligand

4ZTD
4RJF
4D2G

TRAIP
CDK1
P15

3P87

S. Hoffmann(69) KQRVRVKTVPSLFQAKLDTFLWS 30.7 µM
A. Kroker(67)
GRKRRQTSMTDFYHSKRRLIFS
82.6 nM
A. De Biasio(68) GNPVCVRPTPKWQKGIGEFFRLS 5.56 µM
PKDSE
D. Bubeck(66)
DKSGMKSIDTFFGVKNKKKIGKV N/A

2ZVL
2ZVM
2ZVK
1U76

A. Hishiki(65)
A. Hishiki(65)
A. Hishiki(65)
J. Bruning(64)

CIKPNNPKHTLDIFFKPLTH
CAKKGLIDYYLMPSLST
CKRPRPEGMQTLESFFKPLTH
KANRQVSITGFFQRK

4.9µM
0.29 µM
0.4 µM
15.6 µM

Polκ
Polι
Polη
P66

1U7B
1AXC
1VYJ

J. Bruning(64)
J. Gulbis(47)
G.
Kontopidis(70)
T. Bui

SRQGSTQGRLDDFFKVTGSL
GRKRRQTSMTDFYHSKRRLIFS
SAVLQKKITDYFHPKK

60.0 µM
82.6 nM
100 nM

FEN1
P21
PL

APPLPSNILDYFRKTSPT

6.17 µM

ATAD5

Notes

RNASEH2B

1.53 µM with
QRKRRLIFS added to C
terminal

From this study.
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different proteins of the same pathway to bind. The low binding affinities afford the
components (or tools) to be changed on the PCNA (toolbelt) scaffold, allowing it to
facilitate a wide variety of functions while maintaining the hierarchy of binding.
Bruning et al. (2004) reported that the PIP box from p66, a subunit of polδ, binds
to PCNA with an affinity of 15.6 µM (64). Additional contacts outside of the PIP boxes
exists. In vitro studies have shown that most replicative DNA polymerases have nanomolar
affinity for the primer-template junction of DNA, but significantly less affinity for duplex.
Polδ has significantly higher affinity for PCNA when it is loaded onto DNA due to the
additive effects of the PIP box interaction. Reaching a lesion on DNA and stalling of the
replication fork may disrupt its interaction with DNA, allowing other “tools” to replace
polδ to make repairs.
Some proteins have other domains that interact with PCNA when it is modified.
For example, many of the Y-family polymerases contain additional ubiquitin-binding
motifs (UBMs) in the form of ubiquitin binding zinc fingers (UBZs). These UBMs may
allow the Y-family polymerases to bind to PCNA in place of existing proteins at stalled
replication forks (where PCNA is monoubiquitinated). Even without the aid of the UBZ
motif, the PIP-Boxes from Y-family polymerases have been reported to bind from 4.9 µM
up to 290 nM (Table 5). The additional binding between the UBMs and ubiquitin may
facilitate the exchange of polymerases with the normal high-fidelity ones.
We have determined that ATAD5’s PIP box binds to PCNA with low µM affinity
(6.17  0.78 M). Since ATAD5 is also known to recruit the UAF1-USP1 DUB complex
and knockdown of ATAD5 causes an accumulation of ubiquitinated PCNA on chromatin,
we wanted to determine if it directly interacts with ubiquitin. We tested whether or not
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ATAD5 contains a ubiquitin-binding domain using a yeast two-hybrid system and in silico
sequence analysis. There did not appear to be any interaction between ATAD5 and
ubiquitin (data not shown). As an adapter, the combination of ATAD5’s PIP box/PCNA
and SIM/UAF1 interactions may be strong enough to displace the TLS polymerase from
the replication fork after TLS, allowing the ubiquitin to be removed and normal highfidelity polymerases to continue replication.

5.5 Conclusion and future directions
We hypothesized that ATAD5 acts an adaptor that interacts with PCNA and UAF1.
Although we did not assess whether or not ATAD5 was able to interact with these two
proteins at the same time, we were able to characterize the interaction between its PIP box
and SIM with PCNA and UAF1’s SLD2. In our study, we have demonstrated that ATAD5
contains a PIP box and that it interacts with PCNA in the low micromolar range. Based on
the comparison of PIP boxes from other human proteins, we can see that the residues that
make up the hydrophobic plug are important for tuning the affinity of the peptide towards
PCNA. Interactions with the IDCL are also important for binding affinity. Furthermore,
we were able to characterize an interaction between ATAD5 and UAF1.
A SIM on the N-terminal of ATAD5 interacts with the second SLD from UAF1.
We have determined that the interaction between these two polypeptides have a binding
affinity of 20 µM. A mutation on a lysine (K595) to Glu in the second SLD of UAF1
reduced its binding affinity to PCNA 3-fold. Yang et al. (2011) initially made this mutation
based off of a model of the SLD2 domain with SUMO-2, as the corresponding lysine is
critical in SUMO/SIM interactions. The SUMO moiety of sumoylated proteins is able to
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mediate enzyme-substrate interactions and is found in many protein pathways (73).
ATAD5’s SIM may also interact with other sumo-modified proteins. It would be
interesting to assess whether or not ATAD5’s SIM is able to interact with SUMO1-4 or if
it is similar to FANCDI’s (another substrate of the UAF1-USP1 DUB) SIM, which
exclusively interacts with SLDs. Finally, a crystal structure of the complex formed between
the SIM of ATAD5 and SLD2 of UAF1 could provide mechanistic insight on how similar
(if at all) it is to SIM-SUMO interactions.
ATAD5 functions to recruit the UAF1-USP1 DUB complex to monoubiquitinated
PCNA, however, it also functions to unload PCNA during DNA replication. These two
functions are probably separate as previous studies have demonstrated that formation of
the RFC-like complex containing ATAD5 is not required to control levels of PCNA
ubiquitination. The C-terminal is responsible for ATAD5’s association with RFC subunits,
however, the N-terminal 500 amino acids of ATAD5 alone, is sufficient to reduce levels
of monoubiquitinated PCNA. It is unlikely that the PCNA unloading by the RFC-like
complex containing ATAD5 is required in order to deubiquitinate PCNA (72). Previous
reports have knocked down ATAD5 or used partial ATAD5 fragments in their studies (32,
41). With the knowledge of the residues responsible for the interaction between ATAD5
and PCNA, mutations can be made to the full-length protein and studied. Similar
phenotypes to ATAD5 knockdown cells are expected upon DNA damage by DNA
alkylating agents or ionizing radiation. Cells expressing mutant ATAD5 will have an
impaired DNA damage response, leading to increased cell death. More specifically,
monoubiquitinated PCNA will accumulate on chromatin, leading to increased mutation
rates due to prolonged replication by Y-family polymerases and gross genomic instability.
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Furthermore, inactive replication factories will begin to accumulate on DNA and prevent
cell replication and eventually lead to cell death.
Knowledge of how each residue of the PIP box, as well as the flanking residues,
interact with PCNA will allow us to develop more effective drugs to combat cancer.
Inhibition of PCNA at the mRNA and protein level has been shown to inhibit proliferation
and cell growth, sensitizing cancer cells to chemotherapeutic agents. However, no clinical
trials are being conducted on inhibitors of PCNA. Current inhibitors often have low
potency, cell permeability, bioavailability, and undesirable off-target effects (67). A more
thorough understanding of the binding between PCNA and its many binding partners will
allow for effective inhibitors to be developed.
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APPENDIX

Figure I. Vector map of pMCSG9 (left) and pMCSG10 (right). Unique restriction
enzyme cutting sites are indicated along with notable features of the plasmid. Maps were
created with SnapGene Viewer.

Figure II. Vector map of pACT2. Unique restriction enzyme cutting sites are indicated
along with notable features of the plasmid. Maps were created with SnapGene Viewer.
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